Adipsin, MIP-1b, and IL-8 as CSF biomarker panels for ALS diagnosis

Maria Teresa Gonzalez-Garza*, Hector Ramon Martinez, Delia E. Cruz-Vega, Martin Hernandez-Torre, Jorge E. Moreno-Cuevas

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)


Amyotrophic lateral sclerosis (ALS) is an aggressive neurodegenerative disorder that selectively attacks motor neurons in the brain and spinal cord. Despite important advances in the knowledge of the etiology and progression of the disease, there are still no solid grounds in which a clinician could make an early objective and reliable diagnosis from which patients could benefit. Diagnosis is difficult and basically made by clinical rating scales (ALSRs and El Escorial). The possible finding of biomarkers to aid in the early diagnosis and rate of disease progression could serve for future innovative therapeutic approaches. Recently, it has been suggested that ALS has an important immune component that could represent either the cause or the consequence of the disease. In this report, we analyzed 19 different cytokines and growth factors in the cerebrospinal fluid of 77 ALS patients and 13 controls by decision tree and PanelomiX program. Results showed an increase of Adipsin, MIP-1b, and IL-6, associated with a decrease of IL-8 thresholds, related with ALS patients. This biomarker panel analysis could represent an important aid for diagnosis of ALS alongside the clinical and neurophysiological criteria.

Original languageEnglish
Article number3023826
JournalDisease Markers
Publication statusPublished - 1 Jan 2018
Externally publishedYes

Bibliographical note

Publisher Copyright:
Copyright © 2018 Maria Teresa Gonzalez-Garza et al.

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Adipsin, MIP-1b, and IL-8 as CSF biomarker panels for ALS diagnosis'. Together they form a unique fingerprint.

Cite this